Liminatus Pharma Warrants Net Income

Liminatus Pharma Warrants posts a net income of $19B as of September 2024. That is above the sector sector average of $98M. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

For its sector stocks, a net income near $98M is typical. Liminatus Pharma Warrants's $19B is higher that level. That is roughly 19850.8% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Net Income is one piece of Liminatus Pharma Warrants's financial statement story. At $19B, it should be interpreted next to related metrics — for example revenue with costs, assets with liabilities, or income with margins. Stockcircle links those related pages so you can move from this number to the surrounding context quickly.

Context for LIMNW's net income usually means three checks: (1) trend versus prior periods, (2) level versus peers (average $98M), and (3) consistency with growth and profitability. This page covers the first two; Liminatus Pharma Warrants's other metric pages and overview cover the third.